Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep 15;8(9):15708-15.
eCollection 2015.

CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis

Yue Wang  1 , Bo Dai  1 , Dingwei Ye  1
Affiliations

CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis

Yue Wang et al. Int J Clin Exp Med. .

Abstract

Background: CHEK2 encodes for a G2 checkpoint kinase which plays a critical role in DNA repair. Its mutation confers an increased risk of breast cancer. It has also been suggested to increase risks of prostate cancer, but its involvement with this type of cancer has not been confirmed.

Methods: We performed a systematic review and meta-analysis to clarify the association between CHEK2 1100delC, IVS2+1G>A, I157T mutation and risk of Prostate Cancer. A comprehensive, computerized literature search of PubMed until December 27, 2014 was carried out. Eligible studies were included according to specific inclusion criteria. Pooled hazard ratio was estimated using the fixed effects model or random effects model according to heterogeneity between studies.

Results: Eight eligible studies were included in the analysis, all were retrospective studies. The overall meta-analysis demonstrated that the CHEK2 1100delC mutation (OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00) and I157T missense mutation (OR 1.80; 95% confidence interval: 1.51-2.14; P = 0.00) was associated with higher risk of Prostate Cancer, and CHEK2 1100delC mutation is irrelevant to familial aggregation phenomenon of prostate cancer (OR 1.59; 95% confidence interval: 0.79-3.20; P = 0.20). The IVS2+1G>A mutation is also irrelevant to Prostate Cancer (OR = 1.59, 95% CI = 0.93-2.71, P = 0.09). None of the single studies materially altered the original results and no evidence of publication bias was found.

Conclusion: CHEK2 1100delC mutation and I157T missense mutation in males indicates higher risk of Prostate Cancer, but there's no evidence to prove the CHEK2 1100delC mutation was associated with Familial prostate cancer.

Keywords: CHEK2 mutation; Prostate cancer; risk of prostate cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The literature search process. Notes: 63 studies were identified in the primary literature search. 27 potentially relevant studies were further evaluated and eight studies were finally included in the analysis according to the inclusion criteria.
Figure 2
Figure 2
A. Individual study and overall ORs of relationships between CHEK2 1100delC mutation and the risk of prostate cancer. B. Individual study and overall ORs of relationship between CHEK2 1100delC mutation and family prostate cancer cases. C. Individual study and overall ORs of relationships between CHEK2 I157T missense mutation and the risk of prostate cancer. D. Individual study and overall ORs of relationship between CHEK2 IVS2+1G>A mutation and family prostate cancer cases.
Figure 3
Figure 3
A. Test of publication bias of the nanlysis of CHEK2 1100delC mutation and the risk of prostate cancer. B. Test of publication bias of the nanlysis of CHEK2 1100delC mutation and family prostate cancer cases. C. Test of publication bias of the nanlysis of CHEK2 I157T missense mutation and the risk of prostate cancer. D. Test of publication bias of the nanlysis of CHEK2 IVS2+1G>A mutation and family prostate cancer cases.
See this image and copyright information in PMC

References

    1. Nwosu V, Carpten J, Trent JM, Sheridan R. Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Mol Genet. 2001;10:2313–2318. - PubMed
    1. King MC, Marks JH, Mandell JB New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–646. - PubMed
    1. Kim H, Saka B, Knight S, Borges M, Childs E, Klein A, Wolfgang C, Herman J, Adsay VN, Hruban RH, Goggins M. Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis. Clin Cancer Res. 2014;20:1865–1872. - PMC - PubMed
    1. Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res. 2003;63:8153–8157. - PubMed
    1. Johnson N, Fletcher O, Naceur-Lombardelli C, dos Santos Silva I, Ashworth A, Peto J. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study. Lancet. 2005;366:1554–1557. - PubMed

LinkOut - more resources